327 related articles for article (PubMed ID: 38077327)
1. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors.
Liang Y; Wang L; Ma P; Ju D; Zhao M; Shi Y
Front Immunol; 2023; 14():1308264. PubMed ID: 38077327
[TBL] [Abstract][Full Text] [Related]
2. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
Kejamurthy P; Devi KTR
Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
6. Targeting the epigenetic regulation of antitumour immunity.
Hogg SJ; Beavis PA; Dawson MA; Johnstone RW
Nat Rev Drug Discov; 2020 Nov; 19(11):776-800. PubMed ID: 32929243
[TBL] [Abstract][Full Text] [Related]
7. Anticancer natural products targeting immune checkpoint protein network.
Chun KS; Kim DH; Raut PK; Surh YJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
Yin J; Gu T; Chaudhry N; Davidson NE; Huang Y
Front Immunol; 2023; 14():1325615. PubMed ID: 38268926
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
10. Tumor immune checkpoints and their associated inhibitors.
Gao Z; Ling X; Shi C; Wang Y; Lin A
J Zhejiang Univ Sci B; 2022 Oct; 23(10):823-843. PubMed ID: 36226537
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():1956. PubMed ID: 32983126
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
15. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
16. Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy.
Meenakshi S; Maharana KC; Nama L; Vadla UK; Dhingra S; Ravichandiran V; Murti K; Kumar N
Curr Neuropharmacol; 2024; 22(7):1248-1270. PubMed ID: 37605389
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
18. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV.
Benito JM; Restrepo C; García-Foncillas J; Rallón N
Front Immunol; 2023; 14():1270881. PubMed ID: 38130714
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
